Alkem Laboratories · NSE: ALKEM · BSE: 539523
Q1 FY25 results · Apr–Jun 2024
Alkem Laboratories reported revenue from operations of ₹3,031.82 crore (up 2.2% from Q1 FY24) and net profit of ₹550.24 crore (up 91.2% from Q1 FY24) for Q1 FY25 (Apr–Jun 2024), on a consolidated basis.
| Item | Q1 FY25 | Q1 FY24 | YoY | Q4 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 3,031.82 | 2,967.72 | +2.2% | 2,935.82 | +3.3% |
| Other income | 120.31 | 65.84 | +82.7% | 88.17 | +36.5% |
| Total income | 3,152.13 | 3,033.56 | +3.9% | 3,023.99 | +4.2% |
| Profit before tax | 619.36 | 352.85 | +75.5% | 367.34 | +68.6% |
| Net profit for the period | 550.24 | 287.81 | +91.2% | 304.48 | +80.7% |
| Attributable to shareholders of the company | 545.16 | 286.73 | +90.1% | 293.56 | +85.7% |
| EPS, basic (₹) | 45.60 | 23.98 | +90.2% | 24.55 | +85.7% |
| Net margin (%) | 18.1 | 9.7 | 10.4 |
| Item | Q1 FY25 | Q1 FY24 | YoY | Q4 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 2,500.10 | 2,253.17 | +11.0% | 2,365.37 | +5.7% |
| Other income | 106.10 | 64.70 | +64.0% | 83.79 | +26.6% |
| Total income | 2,606.20 | 2,317.87 | +12.4% | 2,449.16 | +6.4% |
| Profit before tax | 640.94 | 318.92 | +101.0% | 389.01 | +64.8% |
| Net profit for the period | 583.25 | 271.44 | +114.9% | 324.97 | +79.5% |
| EPS, basic (₹) | 48.78 | 22.70 | +114.9% | 27.18 | +79.5% |
| Net margin (%) | 23.3 | 12.0 | 13.7 |
Consolidated
- Filed with BSE
- 12 Aug 2024, 12:46 IST
- Board meeting
- 09 Aug 2024
- Period
- 01 Apr 2024 to 30 Jun 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 12 Aug 2024, 12:46 IST
- Board meeting
- 09 Aug 2024
- Period
- 01 Apr 2024 to 30 Jun 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE